The access to drugs and new treatment options is of particular interest for patients for whom conventional treatment strategies have run out, but also for those who do not wish to undergo standard chemotherapy treatments. New molecules are being developed that act as treatment targets and are only accessible by participating in clinical trials. These treatments seem to minimize the systemic side effects of conventional chemotherapy. At MD Anderson Madrid – Hospiten Hematology service, we run several clinical trials for patients with hematologic disease.